Arovella Therapeutics Ltd has released a press release.
Appendix 4D and Half Year Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Arovella licenses novel CAR-iNKT cell armouring technology
- Arovella receives R&D tax credit of $1.94 million
- Arovella licenses novel solid tumour targeting technology
- Reinstatement to Quotation
- Suspension from Quotation
Later from Arovella Therapeutics
- Pause in Trading
- Arovella Completes $12.5M Placement - Funded to Phase 1 Data
- Arovella completes manufacturing scale-up
- Zolpimist Update
- Positive pre-IND feedback from FDA for ALA-101
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics